Arrowhead Pharmaceuticals Q4 2023 Earnings Report
Key Takeaways
Arrowhead Pharmaceuticals announced its financial results for the fiscal year ended September 30, 2023. The company highlighted recent presentations of Phase 2 clinical data and the completion of toxicology studies for pulmonary candidates.
Presented new Phase 2 clinical data from SHASTA-2, MUIR, and ARCHES-2 studies at the American Heart Association Scientific Sessions.
Hosted a webinar featuring experts to discuss plozasiran in the context of lipid and lipoprotein disorder treatments.
Completed chronic GLP toxicology for pulmonary candidates ARO-RAGE and ARO-MMP7 with encouraging results.
Filed for regulatory clearance to initiate a Phase 1/2a study of ARO-DM1 for patients with type 1 myotonic dystrophy.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals
Forward Guidance
Arrowhead Pharmaceuticals did not provide specific financial guidance for future periods in this report.